Manufacturing of CCL module complete

RNS Number : 0631D

Advanced Oncotherapy PLC

26 January 2015

 



26 January 2015

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Manufacturing of CCL module complete

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for treating cancer, announces that the manufacture of the first CCL (Coupled Cavity Linac) module has been successfully completed. This required a complex design procedure and sophisticated manufacturing process achievable only through a successful collaboration between high-level physicists, scientists, engineers and world-leading industrial experience and expertise. 

Following on from their manufacturing agreement with VDL ETG Projects ("VDL") signed in November last year, the Company has been working in close collaboration with VDL to ensure the delivery on-time of this key component for the first LIGHT machine.

The CCL accelerating structures are an essential part of the LIGHT proton therapy system. They consist of a series of cells which accelerate the protons from energies of 37.5 Mega-electron Volts (MeV) to the full 230MeV required to treat all radiosensitive tumours found in a typical clinical setting.

The CCL module has now been shipped to Advanced Oncotherapy's facilities at CERN and will be integrated with the other key components. The development of the other elements of the LIGHT system continue according to plan and the Company will provide further updates on progress throughout the year.

Sanjeev Pandya CEO of Advanced Oncotherapy commented: "We are delighted to have produced the first CCL unit and met this important milestone on time. We could not have reached this target without the competency and know-how of our team at CERN together with our colleagues at VDL. The delivery of this first CCL module has given us the confidence that we remain on target to deliver our first complete LIGHT System on schedule."

Advanced Oncotherapy Plc	www.avoplc.com
Sanjeev Pandya, CEO	Tel: [phone]
Nicolas Serandour, CFO
Westhouse Securities (Nomad & Joint Broker)	Tel: [phone]
Antonio Bossi / David Coaten
Beaufort Securities (Joint Broker)	Tel: [phone]
Saif Janjua / Jon Levinson
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

MSCBIGDBLUDBGUX